The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1292
Methylnaltrexone (Relistor) for Opioid-Induced Constipation
The full article is available to subscribers Subscriber Login   

The FDA has approved subcutaneous injection of methylnaltrexone (Relistor – Wyeth/Progenics), a selective mu-opioid receptor antagonist, for treatment of opioid-induced constipation in patients with advanced illness (such as incurable cancer or end-stage chronic obstructive pulmonary disease) who are receiving palliative care. Another mu-opioid receptor antagonist, alvimopan (Entereg – GlaxoSmithKline/Adolor), has been approved only for short-term, in-hospital use to treat postoperative ileus. It will be reviewed in a future issue.

OPIOID-INDUCED CONSTIPATION — Although patients develop tolerance to the analgesia, respiratory depression and other central-nervous system effects of opioids, they do not develop tolerance to constipation, which can be dose-limiting.1 It is usually treated with laxatives and stool softeners.

MECHANISM OF ACTION — ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Methylnaltrexone (Relistor) for Opioid-Induced Constipation
Article code: 1292b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian